Literature DB >> 18653625

Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection.

K Thorburn1.   

Abstract

BACKGROUND: 600,000 deaths worldwide are estimated to be directly or indirectly attributable to respiratory syncytial virus (RSV).
OBJECTIVES: To determine: (1) the mortality rate; and (2) risk factors for death in children with severe RSV infection.
SETTING: 20-bed, regional, multidisciplinary, tertiary, paediatric intensive care unit (PICU) in a university-affiliated children's hospital.
METHODS: Cohort study of all children with severe RSV infection covering eight consecutive RSV seasons (1999-2007), using PICU admission as a marker of severity.
RESULTS: Of the 406 RSV-positive patients that were admitted to PICU: 98.5% required mechanical ventilation; 35 children died--median age 5.1 months (interquartile range (IQR) 2.4-13.6), length of PICU stay 16 days (IQR 8-31) and 371 survived--median age 2.5 months (IQR 1.2-9), length of PICU stay 5 days (IQR 4-9). The overall PICU RSV mortality was 8.6% with a standardised mortality ratio of 0.76. During the study period 2009 RSV-positive patients were admitted to the children's hospital, giving a hospital RSV mortality rate of 1.7%. Of the deaths, 18 were directly RSV related (RSV bronchiolitis-related mortality PICU 4.4% and hospital 0.9%) as the patients were still RSV positive when they died and 17 children died from non-pneumonitis causes after becoming RSV negative. All of the RSV deaths had pre-existing medical conditions--chromosomal abnormalities 29%, cardiac lesions 27%, neuromuscular 15%, chronic lung disease 12%, large airway abnormality 9%, and immunodeficiency 9%. Nineteen children (56%) had pre-existing disease in two or more organ systems (relative risk (RR) 4.38). Predisposing risk factors for death were pre-existing disease (RR 2.36), cardiac anomaly (RR 2.98) and nosocomial/hospital-acquired RSV infection (RR 2.89). There is an interaction effect between pre-existing disease, nosocomial/hospital-acquired RSV infection and mortality (p<0.001).
CONCLUSIONS: Pre-existing disease/comorbidity, in particular multiple pre-existing diseases and cardiac anomaly, is associated with a significantly higher risk of death from severe RSV infection. Nosocomial/hospital-acquired RSV infection is an additional major risk factor for death in children with severe RSV infection.

Entities:  

Mesh:

Year:  2008        PMID: 18653625     DOI: 10.1136/adc.2008.139188

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  68 in total

Review 1.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

3.  Discharge Criteria for Bronchiolitis: An Unmet Need.

Authors:  Cristina Garcia-Mauriño; Melissa Moore-Clingenpeel; Rebecca Wallihan; Katalin Koranyi; Bavani Rajah; Tiffany Shirk; Maria Vegh; Octavio Ramilo; Asuncion Mejias
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 2.129

4.  Severe adenoviral respiratory infection in children.

Authors:  Michael C Spaeder
Journal:  Intensive Care Med       Date:  2013-03-28       Impact factor: 17.440

5.  Characteristics of severe RSV infection needing intensive care.

Authors:  Bernhard Resch; Katharina Brunner; Siegfried Rödl
Journal:  Eur J Pediatr       Date:  2018-05-08       Impact factor: 3.183

6.  Pediatric Antiviral Stewardship: Defining the Potential Role of Ribavirin in Respiratory Syncytial Virus-Associated Lower Respiratory Illness.

Authors:  Jessica Hoover; Shannan Eades; Weng Man Lam
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

7.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

8.  Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

Authors:  Seung Gu Chang; Moon Sung Park; Jae Eun Yu
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

9.  Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis.

Authors:  Cesar Mella; M Carmen Suarez-Arrabal; Santiago Lopez; Julie Stephens; Soledad Fernandez; Mark W Hall; Octavio Ramilo; Asuncion Mejias
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

10.  Demographic, Clinical and Hematological Profile of Children with Bronchiolitis: A Comparative Study between Respiratory Synctial Virus [RSV] and [Non RSV] Groups.

Authors:  Ganavi Ramagopal; Edin Brow; Alexander Mannu; Jaishree Vasudevan; Lala Umadevi
Journal:  J Clin Diagn Res       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.